Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
Company
Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy
China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...
GE Healthcare Appoints Jeannette Bankes as President and CEO of Patient Care Solutions
GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced this week the appointment of Jeannette Bankes as...
Wantai Bio’s Tuberculosis Test Kit Joins UNOPS StopTB Procurement List
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its Tuberculosis infection...
B. Braun’s DUPLEX System Approved by FDA for Piperacillin and Tazobactam
B. Braun Medical Inc., a US-based healthcare company, announced that the U.S. Food and Drug...
Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...
Peijia Medical’s YonFlow Stent Approved by China’s NMPA
Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...
Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu
Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...
Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...
Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...
Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...
AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...
Yifan Pharma Secures NMPA Approval for Generic Sedapain
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...
Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project
Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans...
HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...
Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU
German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...
Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration...
Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...